<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268788</url>
  </required_header>
  <id_info>
    <org_study_id>2005-130</org_study_id>
    <secondary_id>EudraCT-number: 2005-000934-19</secondary_id>
    <nct_id>NCT00268788</nct_id>
  </id_info>
  <brief_title>Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy</brief_title>
  <official_title>A Controlled Cross-Over Trial of Subcutaneous Versus Intravenous Immunoglobulin for Multifocal Motor Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of subcutaneous administration of
      immunoglobulin compared to intravenous treatment, for multifocal motor neuropathy

      NB. ONLY RECRUITING FROM DENMARK
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction Intravenous immunoglobulin (IVIG) treatment is the only established treatment
      modality in Multifocal Motor Neuropathy (MMN). In order to maintain neuromuscular performance
      patients require lifelong treatment. Hospital-based treatments have high cost and
      inconveniences to patients, particularly in chronic disorders. Immunoglobulin preparations
      are now available for subcutaneous use as IgG replacement therapy. The safety and efficacy of
      subcutaneous infusion is reported to be comparable to i.v. preparations, and has been applied
      successfully in other autoimmune disorders. However patients with MMN have not previously
      been treated with subcutaneous immunoglobulin.

      Hypothesis:

      Subcutaneous immunoglobulin treatment is efficacious and safe with less patient
      inconvenience.

      Primary endpoint:

      Isokinetic muscle strength at the end of treatment A vs B (subcutaneous vs i.v.)

      Secondary endpoint:

      Medical research council score (MRC-score), 9-hole peg test, 10m walking, Nerve conduction
      parameters, SF-36.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Isokinetic muscle strength at the three most affected muscle groups.</measure>
    <time_frame>At the end of each arm of the crossover study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical research council score (MRC-score),</measure>
    <time_frame>At the end of each treatment arm of the crossover study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-hole peg test,</measure>
    <time_frame>At the end of each treatment arm of the crossover study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10m walking,</measure>
    <time_frame>At the end of each treatment arm of the crossover study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve conduction parameters,</measure>
    <time_frame>At the end of each treatment arm of the crossover study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>At the end of each treatment arm of the crossover study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>During each treatment arm of the crossover study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Multifocal Motor Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous Ig given twice a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Ig</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous immunoglobulin</intervention_name>
    <description>Individually dosed, given twice a week.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Subcuvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin</intervention_name>
    <description>Individual dose and frequency</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Endobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Clinical diagnosis of multifocal motor neuropathy, supported by electrophysiological
        findings

        Exclusion Criteria:

          -  Other severe medical conditions

          -  Pregnancy and lactation

          -  Anti-coagulation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Andersen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes Jakobsen, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Neyrology</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2005</study_first_submitted>
  <study_first_submitted_qc>December 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>February 19, 2008</last_update_submitted>
  <last_update_submitted_qc>February 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Thomas Harbo</name_title>
    <organization>Aarhus University Hospital</organization>
  </responsible_party>
  <keyword>multifocal motor neuropathy</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>IVIG</keyword>
  <keyword>gammaglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

